Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000336

Methimazole

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Methimazole, 1-Methyl-2-imidazolethiol, 2-Mercapto-1-methylimidazole

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C4H6N2S
Numéro CAS:
60-56-0
Poids moléculaire :
114.17
Numéro Beilstein :
108646
Numéro MDL:
MFCD00179321
Code UNSPSC :
41116107
ID de substance PubChem :
329830910
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

thiamazole

Fabricant/nom de marque

EDQM

Pf

144-147 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CN1C=CNC1=S

InChI

1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)

Clé InChI

PMRYVIKBURPHAH-UHFFFAOYSA-N

Informations sur le gène

human ... TPO(7173)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Thiamazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H317,H319,H361fd

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

3,3′,5-Triiodo-L-thyronine ≥95% (HPLC), powder

Sigma-Aldrich

T2877

3,3′,5-Triiodo-L-thyronine

Carbamazepine powder

Sigma-Aldrich

C4024

Carbamazepine

1-Methylimidazole ReagentPlus®, 99%

Sigma-Aldrich

M50834

1-Methylimidazole

Ashish A Vyas et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 16(4), 673-676 (2010-05-05)
To report a case of a patient with Graves disease presenting with agranulocytosis induced by methimazole, with subsequent thyroid storm and successful therapeutic use of plasmapheresis. The clinical features and laboratory findings in a patient with agranulocytosis and thyroid storm
Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
Roberto Gastaldi et al.
The Journal of pediatrics, 164(5), 1189-1194 (2014-02-13)
To evaluate clinical and biochemical features of 115 children (98 female, mean age 11.3 ± 3.5 years) with Graves disease to identify possible determinants of remission. We defined as positive outcome the improvement of clinical features and restoration of euthyroidism
T Vogt et al.
The British journal of dermatology, 133(6), 994-996 (1995-12-01)
We report a child with scalp aplasia cutis congenita, whose mother was treated with methimazole during pregnancy. The relationship between antithyroid drug administration during pregnancy and the occurrence of scalp defects is discussed, and the pertinent literature is reviewed.
Glaecir Roseni Mundstock Dias et al.
Neuroendocrinology, 100(1), 45-59 (2014-07-12)
Cellular antioxidant signaling can be altered either by thyroid disturbances or by selenium status. To investigate whether or not dietary diphenyl diselenide can modify the expression of genes of antioxidant enzymes and endpoint markers of oxidative stress under hypothyroid conditions.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique